Neurocrine Biosciences, Inc.
NBIX
$107.00
-$3.60-3.26%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 627.70M | 622.10M | 590.20M | 515.30M | 515.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 627.70M | 622.10M | 590.20M | 515.30M | 515.20M |
| Cost of Revenue | 194.90M | 203.00M | 200.30M | 166.90M | 146.00M |
| Gross Profit | 432.80M | 419.10M | 389.90M | 348.40M | 369.20M |
| SG&A Expenses | 301.80M | 234.30M | 242.00M | 243.10M | 218.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 496.70M | 437.30M | 442.30M | 410.00M | 364.90M |
| Operating Income | 131.00M | 184.80M | 147.90M | 105.30M | 150.30M |
| Income Before Tax | 162.60M | 190.30M | 98.60M | 34.50M | 198.20M |
| Income Tax Expenses | 59.50M | 60.50M | 33.60M | -8.90M | 50.50M |
| Earnings from Continuing Operations | 103.10M | 129.80M | 65.00M | 43.40M | 147.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 103.10M | 129.80M | 65.00M | 43.40M | 147.70M |
| EBIT | 131.00M | 184.80M | 147.90M | 105.30M | 150.30M |
| EBITDA | 138.10M | 191.30M | 155.20M | 111.50M | 156.00M |
| EPS Basic | 1.03 | 1.28 | 0.64 | 0.43 | 1.50 |
| Normalized Basic EPS | 0.96 | 1.29 | 1.06 | 0.80 | 1.07 |
| EPS Diluted | 1.00 | 1.24 | 0.63 | 0.42 | 1.45 |
| Normalized Diluted EPS | 0.93 | 1.25 | 1.03 | 0.77 | 1.03 |
| Average Basic Shares Outstanding | 100.00M | 101.10M | 100.80M | 99.80M | 98.40M |
| Average Diluted Shares Outstanding | 102.90M | 104.30M | 103.90M | 103.60M | 102.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
